Why CEOs Need Advanced Education for Better Drug Development Decisions
Author Information
Author(s): Kramer Peter-Jürgen, Bode Gerd, Bass Rolf
Primary Institution: Technical University of Darmstadt
Hypothesis
CEOs of pharmaceutical companies lack the necessary training in R&D to make informed decisions that impact drug development.
Conclusion
Training CEOs in R&D topics will lead to better decision-making and ultimately benefit both companies and patients.
Supporting Evidence
- CEOs often lack understanding of the R&D process, which can lead to poor decision-making.
- Training programs for R&D staff exist, but similar programs for CEOs are lacking.
- Effective communication between R&D staff and CEOs is crucial for successful drug development.
Takeaway
CEOs need to learn more about drug research so they can make smarter choices that help create better medicines faster.
Methodology
The paper discusses the need for specialized training for CEOs in R&D to improve decision-making in pharmaceutical companies.
Potential Biases
Potential bias may arise from the authors' affiliations with institutions involved in pharmaceutical education.
Limitations
The paper does not provide empirical data to support the claims made about the impact of CEO training on drug development outcomes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website